Latest News & Features
Americas
Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen. 7 September 2021
Americas
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market. 7 September 2021
Americas
In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis. 6 September 2021
Medtech
The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial. 2 September 2021
Americas
Belcher’s chief science officer deceived the US Patent and Trademark Office in order to obtain a patent, the US Court of Appeals for the Federal Circuit has ruled in a win for Pfizer’s subsidiary, Hospira. 2 September 2021
Generics
The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made. 2 September 2021
Americas
A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital. 31 August 2021
Americas
Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule. 31 August 2021
Big Pharma
South Korean officials have urged the US government to help Korean companies gain access to IP related to producing COVID-19 jabs. 31 August 2021
Americas
Kite Pharma has successfully persuaded the US Court of Appeals for the Federal Circuit to reverse a $1.2 billion win for the Bristol-Meyers Squibb owned Juno Therapeutics over a cancer treatment patent. 26 August 2021